Loading
Cabozantinib delayed progression in previously treated advanced neuroendocrine tumours of both pancreatic and extra-pancreatic origin compared with placebo, adding a new option after somatostatin analogues, everolimus or radioligand therapy.
Two parallel phase 3 placebo-controlled trials of cabozantinib in 298 patients with progressive advanced neuroendocrine tumours: 203 with extra-pancreatic (including lung and small bowel) and 95 with pancreatic tumours, all previously treated.
Median progression-free survival was 8.4 versus 3.9 months in extra-pancreatic tumours (hazard ratio 0.38) and 13.8 versus 4.4 months in pancreatic tumours (hazard ratio 0.23); hypertension, fatigue and diarrhoea were common.
Cabozantinib is approved for previously treated neuroendocrine tumours of any origin and is a standard later-line choice, including for lung carcinoids.
Shares Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, New England Journal of Medicine.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.